Uganda begins lenacapavir rollout for HIV prevention amid mixed reviews

Lenacapavir, a new injection that offers six months of protection against HIV, is being rolled out in Uganda, sparking both hope and skepticism among health officials and communities. The drug is designed for HIV-negative individuals as a form of pre-exposure prophylaxis (PrEP) and is a significant development in the fight against the disease, which currently affects 13% of people in the region.

The rollout comes at a critical time as the HIV epidemic continues to impact many lives across sub-Saharan Africa. Irene, a 22-year-old participant in a clinical trial for lenacapavir, shared her motivation for joining the study, which was influenced by her uncle’s struggle with HIV. In her district, where stigma around HIV is prevalent, Irene’s participation represents a broader effort to combat the disease and provides a beacon of hope for others at risk.

Clinical trials, including the PURPOSE 1 and 2 studies, have shown lenacapavir to be remarkably effective. An independent committee halted the randomized phase early due to the drug's success, allowing all participants access. Recent data presented at the International AIDS Conference confirmed that out of nearly 4,200 women in the PURPOSE 1 trial, none acquired HIV after being offered lenacapavir. Furthermore, over 96% of participants adhered to the treatment schedule, showcasing the potential for this long-acting injection to improve health outcomes.

Despite the promising results, challenges remain. Some experts express concerns about the rollout and ongoing access to the drug. As lenacapavir becomes more available, its impact on HIV transmission and community acceptance will be closely monitored. This could change the landscape of HIV prevention, especially for women, who are disproportionately affected in the region. The future of HIV care may hinge on the successful integration of lenacapavir into existing health systems.